PolTREG and the Medical Research Agency have entered into an agreement to implement and financially support a project entitled “Cell therapy for prediabetes based on artificially multiplied CD4+CD25+CD127 – regulatory lymphocytes and anti-CD20 antibody.”
The total cost of the project, which is eligible for funding, is PLN 49.5 million. The grant awarded for this purpose has a value of PLN 31.7 million. The project implementation period shall conclude on 24 November 2028.
The objective of this agreement is to conduct industrial research and development with the aim of conducting clinical trials and, ultimately, implementing an innovative cell therapy for patients in the prediabetes phase of type 1 diabetes. The planned research tasks include the preparation and execution of a Phase II clinical trial.